|
|
next generation gene delivery
Ablitech's Versadel platform technology addresses the need for efficient targeted delivery of biomolecules in therapeutic applications. Versadel gene therapy is Ablitech's initial focus for this platform biomolecule delivery technology.
|
|
ABLITECH NEWS
09.23.09 Ablitech receives $100,000 investment from Mississippi Seed Fund.
read more
05.02.08 Ablitech granted Phase I funding from the National Science Foundation.
read more
|
Versadel
from Ablitech, Inc.
Gene therapy has been long considered to be a game-changing technology for the treatment of diseases. However, the delivery of genetic material to target cells has been a major hindrance for getting these therapies to the market.
Ablitech has developed Versadel - a gene delivery system that overcomes these delivery hurdles. Ablitech's first product using the Versadel platform is for the treatment of pancreatic cancer.
|
|
